Opendata, web and dolomites

OXYPREM SIGNED

Precise brain oxygen monitoring for high-risk preterm infants

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXYPREM project word cloud

Explore the words cloud of the OXYPREM project. It provides you a very rough idea of what is the project "OXYPREM" about.

435    business    global    oxyprem    annually    62    translates    initially    near    running    fixed    born    supply    capitalizing    opportunity    damage    neonatologists    5x    respiratory    transforming    unmet    immature    reducing    ag    oxygenation    paralysis    intensive    alerting    company    reusable    decrease    care    head    consists    die    therapy    medical    answer    swiss    meant    grow    o2    adults    created    monitor    infrared    saturation    easier    oximeters    irreversible    urgent    opposed    sensor    commercialization    competitors    preterms    deaths    spin    impairment    market    quality    algorithms    million    precision    preterm    clinical    oxygen    silicone    2024    neurodevelopment    disposable    world    prototypes    ones    designed    chronic    biocompatible    neonatal    university    brain    life    tissue    variation    unnecessary    little    spectroscopy    worth    15    actual    degree    compelling    viability    billion    cardiovascular    reliability    disabilities    shown    globally    cagr2017    variations    off    nirs    surviving    oximeter    babies    savings    lacking    levels    signals    zurich   

Project "OXYPREM" data sheet

The following table provides information about the project.

Coordinator
OXYPREM AG 

Organization address
address: FRAUENKLINIKSTRASSE 10
city: ZURICH
postcode: 8091
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXYPREM AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Globally, 15 million preterm babies are born annually (435,000 in Europe), from which 1 million die. Even when surviving, they may face disabilities, such as neurodevelopment impairment or paralysis. Since their respiratory and cardiovascular systems are immature, they need early oxygen (O2) therapy. Tissue oximeters are medical devices needed to monitor the actual level of O2 supply in their brain, since little O2 variations can produce irreversible damage. However, current devices are adapted from tissue oximeters initially meant for adults, lacking the precision and reliability preterm babies need. World leading neonatologists have been alerting about the urgent need to develop tissue oximeters specifically designed for preterms, to decrease unnecessary deaths and chronic disabilities. OxyPrem is our answer: a brain oximeter created just for preterm babies and providing the degree of precision and reliability they need. OxyPrem consists of (1) a high-quality Near-Infrared Spectroscopy (NIRS) sensor embedded in biocompatible silicone that is fixed to the preterm's head to monitor brain O2-levels, and a (2) monitor running advanced analysis algorithms transforming the signals into tissue oxygenation saturation measurements. OxyPrem prototypes have shown unmet levels of precision in clinical studies, reducing 5x the variation observed with competitors. Furthermore, our reusable sensor (opposed to the disposable ones from competitors), translates into important savings. OxyPrem represents a compelling business opportunity, capitalizing from the global neonatal intensive care market, worth €5.6 billion and expected to grow at a CAGR2017-2024 of 5.62%. The commercialization of OxyPrem is key to the viability of our company OxyPrem AG, a Swiss spin-off from University of Zurich, born to make preterm life's easier.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXYPREM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXYPREM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More